Kamada Intensifies Efforts to Highlight CYTOGAM's Role in CMV Management for Transplant Patients

Kamada Ltd., a global biopharmaceutical company, is stepping up its efforts to support organ transplant patients and their healthcare providers in managing cytomegalovirus (CMV) through its treatment, CYTOGAM®. CMV, while generally harmless to those with healthy immune systems, poses significant risks to organ transplant recipients, with 20% to 60% developing symptomatic infections post-transplant. CYTOGAM, an intravenous immunoglobulin, is designed to prevent CMV disease in kidney, lung, liver, pancreas, and heart transplant patients by complementing standard antiviral treatments.

The company has announced a new post-marketing research program aimed at generating data to support CYTOGAM's benefits, including exploring late-onset CMV prevention, alternative dosing strategies, and potential new applications. This initiative reflects Kamada's dedication to improving CMV disease management and patient outcomes, addressing a critical need in the transplantation field where CMV remains a leading cause of graft rejection and mortality.

Kamada's commitment is underscored by its collaboration with Key Opinion Leaders (KOLs) and its presentation of research findings at major medical conferences. These efforts highlight CYTOGAM's potential to enhance patient care and its superiority over regular immune globulin intravenous (IVIG) in combating CMV. With CYTOGAM's revenue showing a 31% increase in 2024, Kamada's intensified focus on research and awareness could further solidify its position in the market and, more importantly, improve the lives of transplant patients at risk of CMV disease.